|
1
|
Wang SJ, Gao Y, Chen H, Kong R, Jiang HC,
Pan SH, Xue DB, Bai XW and Sun B: Dihydroartemisinin inactivates
NF-kappaB and potentiates the anti-tumor effect of gemcitabine on
pancreatic cancer both in vitro and in vivo. Cancer Lett.
293:99–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo X and Cui Z: Current diagnosis and
treatment of pancreatic cancer in China. Pancreas. 31:13–22. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bednar F and Simeone DM: Pancreatic cancer
stem cell biology and its therapeutic implications. J
Gastroenterol. 46:1345–1352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Castellanos JA, Merchant NB and
Nagathihalli NS: Emerging targets in pancreatic cancer:
Epithelial-mesenchymal transition and cancer stem cells. Onco
Targets Ther. 6:1261–1267. 2013.PubMed/NCBI
|
|
7
|
Xia J, Chen C, Chen Z, Miele L, Sarkar FH
and Wang Z: Targeting pancreatic cancer stem cells for cancer
therapy. Biochim Biophys Acta. 1826:385–399. 2012.PubMed/NCBI
|
|
8
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y,
Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor,
induces an oxidative stress-independent growth inhibition of
pancreatic cancer cells through G2/M cell-cycle arrest and
apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Chen Z, Zong Y, Gong F, Zhu Y, Zhu
Y, Lv J, Zhang J, Xie L, Sun Y, et al: PP2A inhibitors induce
apoptosis in pancreatic cancer cell line PANC-1 through persistent
phosphorylation of IKKα and sustained activation of the NF-κB
pathway. Cancer Lett. 304:117–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Chen Z, Gong FR, Zong Y, Chen K, Li
DM, Yin H, Duan WM, Miao Y, Tao M, et al: Growth of the pancreatic
cancer cell line PANC-1 is inhibited by protein phosphatase 2A
inhibitors through overactivation of the c-Jun N-terminal kinase
pathway. Eur J Cancer. 47:2654–2664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu MY, Xie X, Xu ZK, Xie L, Chen Z, Shou
LM, Gong FR, Xie YF, Li W and Tao M: PP2A inhibitors suppress
migration and growth of PANC-1 pancreatic cancer cells through
inhibition on the Wnt/β-catenin pathway by phosphorylation and
degradation of β-catenin. Oncol Rep. 32:513–522. 2014.PubMed/NCBI
|
|
13
|
Xie X, Wu MY, Shou LM, Chen LP, Gong FR,
Chen K, Li DM, Duan WM, Xie YF, Mao YX, et al: Tamoxifen enhances
the anticancer effect of cantharidin and norcantharidin in
pancreatic cancer cell lines through inhibition of the protein
kinase C signaling pathway. Oncol Lett. 9:837–844. 2015.PubMed/NCBI
|
|
14
|
Honkanen RE: Cantharidin, another natural
toxin that inhibits the activity of serine/threonine protein
phosphatases types 1 and 2A. FEBS Lett. 330:283–286. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prakash N and Wurst W: A Wnt signal
regulates stem cell fate and differentiation in vivo. Neurodegener
Dis. 4:333–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui J, Jiang W, Wang S, Wang L and Xie K:
Role of Wnt/β-catenin signaling in drug resistance of pancreatic
cancer. Curr Pharm Des. 18:2464–2471. 2012. View Article : Google Scholar
|
|
17
|
Gresham GK, Wells GA, Gill S, Cameron C
and Jonker DJ: Chemotherapy regimens for advanced pancreatic
cancer: A systematic review and network meta-analysis. BMC Cancer.
14:4712014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shou LM, Zhang QY, Li W, Xie X, Chen K,
Lian L, Li ZY, Gong FR, Dai KS, Mao YX, et al: Cantharidin and
norcantharidin inhibit the ability of MCF-7 cells to adhere to
platelets via protein kinase C pathway-dependent downregulation of
α2 integrin. Oncol Rep. 30:1059–1066. 2013.PubMed/NCBI
|
|
19
|
Reghunathan R, Bi C, Liu SC, Loong KT,
Chung TH, Huang G and Chng WJ: Clonogenic multiple myeloma cells
have shared stemness signature associated with patient survival.
Oncotarget. 4:1230–1240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee CJ, Li C and Simeone DM: Human
pancreatic cancer stem cells: Implications for how we treat
pancreatic cancer. Transl Oncol. 1:14–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong SP, Wen J, Bang S, Park S and Song
SY: CD44-positive cells are responsible for gemcitabine resistance
in pancreatic cancer cells. Int J Cancer. 125:2323–2331. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reim F, Dombrowski Y, Ritter C, Buttmann
M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl
J, et al: Immunoselection of breast and ovarian cancer cells with
trastuzumab and natural killer cells: Selective escape of
CD44high/CD24low/HER2low breast cancer stem
cells. Cancer Res. 69:8058–8066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yabuuchi S, Pai SG, Campbell NR, de Wilde
RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M,
Maitra A, et al: Notch signaling pathway targeted therapy
suppresses tumor progression and metastatic spread in pancreatic
cancer. Cancer Lett. 335:41–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B,
Welling TH, Pasca di Magliano M and Simeone DM: c-Met is a marker
of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227. e22152011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rasheed ZA and Matsui W: Biological and
clinical relevance of stem cells in pancreatic adenocarcinoma. J
Gastroenterol Hepatol. 27(Suppl 2): S15–S18. 2012. View Article : Google Scholar
|
|
29
|
Richard V, Nair MG, Santhosh Kumar TR and
Pillai MR: Side population cells as prototype of chemoresistant,
tumor-initiating cells. BioMed Res Int. 2013:5172372013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Marhaba R, Klingbeil P, Nuebel T,
Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM:
Cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jothy S: CD44 and its partners in
metastasis. Clin Exp Metastasis. 20:195–201. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klingbeil P, Marhaba R, Jung T, Kirmse R,
Ludwig T and Zöller M: CD44 variant isoforms promote metastasis
formation by a tumor cell-matrix cross-talk that supports adhesion
and apoptosis resistance. Mol Cancer Res. 7:168–179. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Malanchi I, Peinado H, Kassen D, Hussenet
T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, et
al: Cutaneous cancer stem cell maintenance is dependent on
beta-catenin signalling. Nature. 452:650–653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chong JM and Speicher DW: Determination of
disulfide bond assignments and N-glycosylation sites of the human
gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4,
KSA, and Ep-CAM). J Biol Chem. 276:5804–5813. 2001. View Article : Google Scholar
|
|
36
|
Trebak M, Begg GE, Chong JM, Kanazireva
EV, Herlyn D and Speicher DW: Oligomeric state of the colon
carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its
role in GA733-mediated homotypic cell-cell adhesion. J Biol Chem.
276:2299–2309. 2001. View Article : Google Scholar
|
|
37
|
Mohan A, Nalini V, Mallikarjuna K,
Jyotirmay B and Krishnakumar S: Expression of motility-related
protein MRP1/ CD9, N-cadherin, E-cadherin, alpha-catenin and
beta-catenin in retinoblastoma. Exp Eye Res. 84:781–789. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamashita T, Budhu A, Forgues M and Wang
XW: Activation of hepatic stem cell marker EpCAM by
Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res.
67:10831–10839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guillemot JC, Naspetti M, Malergue F,
Montcourrier P, Galland F and Naquet P: Ep-CAM transfection in
thymic epithelial cell lines triggers the formation of dynamic
actin-rich protrusions involved in the organization of epithelial
cell layers. Histochem Cell Biol. 116:371–378. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-myc and induces cell proliferation. Oncogene. 23:5748–5758. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Osta WA, Chen Y, Mikhitarian K, Mitas M,
Salem M, Hannun YA, Cole DJ and Gillanders WE: EpCAM is
overexpressed in breast cancer and is a potential target for breast
cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baeuerle PA and Gires O: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oonishi K, Cui X, Hirakawa H, Fujimori A,
Kamijo T, Yamada S, Yokosuka O and Kamada T: Different effects of
carbon ion beams and X-rays on clonogenic survival and DNA repair
in human pancreatic cancer stem-like cells. Radiother Oncol.
105:258–265. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ohara Y, Oda T, Sugano M, Hashimoto S,
Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K,
et al: Histological and prognostic importance of CD44(+) /CD24(+) /
EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci.
104:1127–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herreros-Villanueva M, Zubia-Olascoaga A
and Bujanda L: c-Met in pancreatic cancer stem cells: Therapeutic
implications. World J Gastroenterol. 18:5321–5323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rasheed ZA, Yang J, Wang Q, Kowalski J,
Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et
al: Prognostic significance of tumorigenic cells with mesenchymal
features in pancreatic adenocarcinoma. J Natl Cancer Inst.
102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ding Q, Miyazaki Y, Tsukasa K, Matsubara
S, Yoshimitsu M and Takao S: CD133 facilitates
epithelial-mesenchymal transition through interaction with the ERK
pathway in pancreatic cancer metastasis. Mol Cancer. 13:152014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Andrade AC, Nilsson O, Barnes KM and Baron
J: Wnt gene expression in the post-natal growth plate: Regulation
with chondrocyte differentiation. Bone. 40:1361–1369. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shafee N, Smith CR, Wei S, Kim Y, Mills
GB, Hortobagyi GN, Stanbridge EJ and Lee EY: Cancer stem cells
contribute to cisplatin resistance in Brca1/p53-mediated mouse
mammary tumors. Cancer Res. 68:3243–3250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Todaro M, Alea MP, Di Stefano AB,
Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G,
Medema JP, et al: Colon cancer stem cells dictate tumor growth and
resist cell death by production of interleukin-4. Cell Stem Cell.
1:389–402. 2007. View Article : Google Scholar
|
|
52
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ciliberto D, Botta C, Correale P, Rossi M,
Caraglia M, Tassone P and Tagliaferri P: Role of gemcitabine-based
combination therapy in the management of advanced pancreatic
cancer: A meta-analysis of randomised trials. Eur J Cancer.
49:593–603. 2013. View Article : Google Scholar
|
|
55
|
Ko AH, Dito E, Schillinger B, Venook AP,
Xu Z, Bergsland EK, Wong D, Scott J, Hwang J and Tempero MA: A
phase II study evaluating bevacizumab in combination with
fixed-dose rate gemcitabine and low-dose cisplatin for metastatic
pancreatic cancer: Is an anti-VEGF strategy still applicable?
Invest New Drugs. 26:463–471. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nedaeinia R, Avan A, Manian M, Salehi R
and Ghayour-Mobarhan M: EGFR as a potential target for the
treatment of pancreatic cancer: Dilemma and controversies. Curr
Drug Targets. 15:1293–1301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar
|
|
58
|
Lee CJ, Dosch J and Simeone DM: Pancreatic
cancer stem cells. J Clin Oncol. 26:2806–2812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Seguin L, Kato S, Franovic A, Camargo MF,
Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, et
al: An integrin β3-KRAS-RalB complex drives tumour stemness and
resistance to EGFR inhibition. Nat Cell Biol. 16:457–468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yilmaz OH, Valdez R, Theisen BK, Guo W,
Ferguson DO, Wu H and Morrison SJ: Pten dependence distinguishes
haematopoietic stem cells from leukaemia-initiating cells. Nature.
441:475–482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and
Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic
stem cells. Nat Med. 12:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jones RJ, Matsui WH and Smith BD: Cancer
stem cells: Are we missing the target? J Natl Cancer Inst.
96:583–585. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Dingli D and Michor F: Successful therapy
must eradicate cancer stem cells. Stem Cells. 24:2603–2610. 2006.
View Article : Google Scholar : PubMed/NCBI
|
